Halozyme Therapeutics, Inc. (NASDAQ:HALO) Forecasted to Post Q2 2024 Earnings of $0.68 Per Share

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Investment analysts at Zacks Research decreased their Q2 2024 earnings per share estimates for shares of Halozyme Therapeutics in a research note issued to investors on Monday, June 10th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will earn $0.68 per share for the quarter, down from their previous estimate of $0.74. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.66 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q3 2024 earnings at $0.91 EPS, Q4 2024 earnings at $1.14 EPS, FY2024 earnings at $3.46 EPS, Q1 2025 earnings at $0.89 EPS, Q2 2025 earnings at $1.06 EPS, Q3 2025 earnings at $1.09 EPS, Q4 2025 earnings at $1.22 EPS, FY2025 earnings at $4.27 EPS, Q1 2026 earnings at $1.44 EPS and FY2026 earnings at $5.66 EPS.

Several other analysts also recently issued reports on HALO. TD Cowen initiated coverage on Halozyme Therapeutics in a report on Thursday, February 29th. They issued an “outperform” rating and a $54.00 price target for the company. JMP Securities decreased their price objective on shares of Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating for the company in a research report on Wednesday, May 8th. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Halozyme Therapeutics in a research report on Tuesday, June 4th. StockNews.com raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, February 23rd. Finally, Wells Fargo & Company upped their price objective on shares of Halozyme Therapeutics from $48.00 to $58.00 and gave the company an “overweight” rating in a research report on Friday, June 7th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $54.13.

Halozyme Therapeutics Stock Down 0.2 %

Shares of NASDAQ HALO opened at $49.50 on Thursday. Halozyme Therapeutics has a 12-month low of $32.83 and a 12-month high of $53.00. The company has a market cap of $6.30 billion, a P/E ratio of 20.45, a P/E/G ratio of 0.50 and a beta of 1.28. The company has a current ratio of 6.64, a quick ratio of 5.36 and a debt-to-equity ratio of 8.44. The stock has a fifty day moving average price of $42.82 and a 200 day moving average price of $39.66.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.07. Halozyme Therapeutics had a return on equity of 225.71% and a net margin of 36.94%. The firm had revenue of $195.88 million during the quarter, compared to the consensus estimate of $201.72 million.

Insider Transactions at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $38.49, for a total transaction of $384,900.00. Following the transaction, the senior vice president now owns 168,176 shares of the company’s stock, valued at $6,473,094.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last 90 days, insiders have sold 30,000 shares of company stock valued at $1,338,800. Insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Halozyme Therapeutics

Large investors have recently bought and sold shares of the business. Rise Advisors LLC bought a new position in Halozyme Therapeutics in the first quarter worth about $25,000. Whittier Trust Co. bought a new position in Halozyme Therapeutics in the first quarter worth about $27,000. Principal Securities Inc. bought a new position in Halozyme Therapeutics in the fourth quarter worth about $34,000. Fidelis Capital Partners LLC bought a new position in Halozyme Therapeutics in the first quarter worth about $52,000. Finally, First Horizon Advisors Inc. lifted its holdings in Halozyme Therapeutics by 24.5% in the fourth quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 293 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.